z-logo
open-access-imgOpen Access
Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort
Author(s) -
Baleanu Felicia,
Bergmann Pierre,
Hambye Anne Sophie,
Dekelver Carole,
Iconaru Laura,
Cappelle Sylvie I.,
Moreau Michel,
Paesmans Marianne,
Karmali Rafik,
Body JeanJacques
Publication year - 2019
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.13347
Subject(s) - medicine , frax , trabecular bone score , cohort , bone mineral , cohort study , diabetes mellitus , body mass index , type 2 diabetes , epidemiology , osteoporosis , prospective cohort study , physical therapy , endocrinology , quantitative computed tomography , osteoporotic fracture
Abstract Objective The purpose of our study was to compare bone mineral density (BMD) and trabecular bone score (TBS) values between patients with type 2 diabetes (T2D) and control subjects with similar FRAX scores in order to evaluate TBS as an additional tool for assessing fracture risk in diabetic subjects. Methods A cross‐sectional analysis was performed using BMD results from 260 subjects participating in the FRISBEE study (Fracture RISk Brussels Epidemiological Enquiry), an ongoing prospective epidemiological study in a population‐based cohort (Brussels, Belgium) of 3560 postmenopausal women aged 60‐85 years. TBS measurement was possible in 1108 subjects from the FRISBEE cohort. Among these 1108 subjects, 65 had known T2D at inclusion. For each diabetic case we selected 3 controls from our database. (n = 195). Diabetic subjects and controls were matched for age and baseline FRAX score for major osteoporotic fractures. Results BMD (g/cm 2 ) tended to be higher in T2D than in control subjects, significantly so at the total hip 0.90 ± 0.13 versus 0.87 ± 0.12 ( P  = 0.015). On the contrary, TBS was significantly lower in the T2D group (mean = 1.19 ± 0.17) compared with the control group (mean = 1.27 ± 0.13) ( P  = 0.005). Mean TBS remained significantly lower in T2D (1.22 ± 0.17) compared with the control group (1.27 ± 0.13) ( P  = 0.02) after adjustment for body mass index. Conclusion Our data suggest that TBS complements BMD at the total hip, in demonstrating the “diabetes‐associated bone disease”.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here